Markers for Inflammation and Oxidative Stress in Patients with Coronary Artery Disease and Microvascular Disease – Is there a Difference?

1. Runev N, Manov E. Diastolic left ventricular dysfunction – invasive assessment. 1st edition Maurice-France; LAP LAMBERT Academic Publishing 2014.Search in Google Scholar

2. Jasmin Č. Procedural Techniques of Coronary Angiography. Advances in the diagnosis of Coronary Atherosclerosis 2011;6: 95-121.Search in Google Scholar

3. Hector M, Gogas B, Serruys P, et al. IVUS-based imaging modalities for tissue characterization: similarities and differences. Int J Cardiovasc Imaging 2011;21:215-224.Search in Google Scholar

4. Davi G, Guagnano M, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-2014.10.1001/jama.288.16.200812387653Search in Google Scholar

5. Davi G, Ciabattoni G, Consoli M, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99:224-229.10.1161/01.CIR.99.2.224Search in Google Scholar

6. Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002;106:2800-2805.10.1161/01.CIR.0000039528.49161.E9Search in Google Scholar

7. Lavie L, Lavie P. Molecular mechanisms of cardioavascular disease in OSAHS: The oxidative stress link. European Resp J.2009;33:1467-1484.10.1183/09031936.0008660819483049Search in Google Scholar

8. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J.2009;73:411-418.10.1253/circj.CJ-08-110219194043Search in Google Scholar

9. Wu J, Stevenson M, Brown J, et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol. 2008;28:698-704.10.1161/ATVBAHA.107.16090318276908Search in Google Scholar

10. Witteles R, Fowler M. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51:93-102.10.1016/j.jacc.2007.10.02118191731Search in Google Scholar

11. Bassuk S, Rifai N, Ridker P. High sensitive C-reactive protein: clinical importance. Curr. Probl. Cardiol 2004;29:439-493.Search in Google Scholar

12. Tomai F, Ribichini F, Ghini A, et al. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. European Heart Journal 2005;26:2099-2105.10.1093/eurheartj/ehi35615961409Search in Google Scholar

13. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. European Heart Journal 2010;31:777-783.10.1093/eurheartj/ehq02220185554Search in Google Scholar

14. Gencer B, Auer R, Rekeneire N, et al. Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis 2016;245:181-186.10.1016/j.atherosclerosis.2015.12.004569567726724528Search in Google Scholar

15. Reilly M, Lehrke M, Wolfe M, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-939.10.1161/01.CIR.0000155620.10387.4315710760Search in Google Scholar

16. Tsioufis C, Dimitriadis K, Selima M, et al. Association of resistin with urinary albumin excretion in nondiabetic patients with essential hypertension. Am J Hypertens 2010; 23(6),681-686.10.1038/ajh.2010.3420203628Search in Google Scholar

17. Sinan U, Canbolat I, Baydar O, et al. Relationship between increased serum resistin level and severity of coronary artery disease. Angiology 2014; 65:239-242.10.1177/000331971350271824052521Search in Google Scholar